Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II

Treatment

Completed

18 and over

Pharmaceutical / Industry

PCYC-0215
NCT00096837

Trial Description

Summary

The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.

Eligibility Criteria

Inclusion Criteria:

Relapsed or Refractory Multiple Myeloma

≥ 18 years old

Able to provide consent for participation

ECOG status 0-2

Lab values:

ANC ≥ 1,000/µL

WBC count ≥ 2.0/µL

Hemoglobin ≥ 8.0 g/dL

Platelet count ≥ 50,000/µL

AST and ALT ≤ 2 x ULN

Total Bilirubin ≤ 2 x ULN

Creatinine ≤ 2.0 mg/dL

and

Not pregnant or lactating

Trial Contact Information

Trial Lead Organizations/Sponsors

Pharmacyclics, Incorporated

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00096837
Information obtained from ClinicalTrials.gov on May 27, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.